[1] Shao YJ, Ji K, Hao JL, et al. Nonpain symptom prevalence and intensity of inpatients with moderate to severe cancer pain in China[J]. Am J Hosp Palliat Care, 2016, 33(5): 448-455. DOI: 10.1177/1049909114565109.
[2] Wong FC, Lee TW, Yuen KK, et al. Intercostal nerve blockade for cancer pain: effectiveness and selection of patients[J]. Hong Kong Med J, 2007, 13(4): 266-270.
[3] Gulati A, Shah R, Puttanniah V, et al. A retrospective review and treatment paradigm of interventional therapies for patients suffering from intractable thoracic chest wall pain in the oncologic population[J]. Pain Med, 2015, 16(4): 802-810. DOI: 10.1111/pme.12558.
[4] Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial[J]. JAMA, 2004, 291(9): 1092-1099. DOI: 10.1001/jama.291.9.1092.
[5] Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer[J]. Am J Gastroenterol, 2007, 102(2): 430-438. DOI: 10.1111/j.15720241.2006.00967.x.
[6] Zhang CL, Zhang TJ, Guo YN, et al. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain[J]. Dig Dis Sci, 2008, 53(3): 856-860. DOI: 10.1007/s1062000799052.
[7] Wyse JM, Carone M, Paquin SC, et al. Randomized, doubleblind, controlled trial of early endoscopic ultrasoundguided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer[J]. J Clin Oncol, 2011, 29(26): 3541-3546. DOI: 10.1200/JCO.2010.32.2750.
[8] Zhong W, Yu Z, Zeng JX, et al. Celiac plexus block for treatment of pain associated with pancreatic cancer: a metaanalysis[J]. Pain Pract, 2014, 14(1): 43-51. DOI: 10.1111/papr.12083.
[9] Mercadante S, Klepstad P, Kurita GP, et al. Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations[J]. Crit Rev Oncol Hematol, 2015, 96(3): 577-583. DOI: 10.1016/j.critrevonc.2015.07.014.
[10] Suleyman ON, Talu GK, Camlica H, et al. Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain[J]. Eur J Pain, 2004, 8(6): 539-545. DOI: 10.1016/j.ejpain.2004.01.001.
[11] Pello S, Miller A, Ku T, et al. Hemorrhagic gastritis and duodenitis following celiac plexus neurolysis[J]. Pain Physician, 2009, 12(6): 1001-1003.
[12] Staats PS, Hekmat H, Sauter P, et al. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a doubleblind, randomized, placebocontrolled study[J]. Pain Med, 2001, 2(1): 28-34. DOI: 10.1046/j.15264637.2001.002001028.x.
[13] Amr YM, Makharita MY. Comparative study between 2 protocols for management of severe pain in patients with unresectable pancreatic cancer: oneyear followup[J]. Clin J Pain, 2013, 29(9): 807-813. DOI: 10.1097/AJP.0b013e3182757673.
[14] Kroll CE, Schartz B, GonzalezFernandez M, et al. Factors associated with outcome after superior hypogastric plexus neurolysis in cancer patients[J]. Clin J Pain, 2014, 30(1): 55-62. DOI: 10.1097/AJP.0b013e3182869d68.
[15] Mishra S, Bhatnagar S, Rana SP, et al. Efficacy of the anterior ultrasoundguided superior hypogastric plexus neurolysis in pelvic cancer pain in advanced gynecological cancer patients[J]. Pain Med, 2013, 14(6): 837-842. DOI: 10.1111/pme.12106.
[16] Plancarte RS, MayerRivera FJ. Radiofrequency procedures for sacral and pelvic region pain[J]. Pain Pract, 2002, 2(3): 248-249. DOI: 10.1046/j.15332500.2002.02031.x.
[17] 贾和平, 金瑞林, 李英杰, 等. 经骶尾椎间盘穿刺毁损奇神经节对会阴部晚期癌痛患者的疗效[J]. 中华麻醉学杂志, 2008, 28(4): 376-377. DOI: 10.3321/j.issn:02541416.2008.04.012.
[18] Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain[J]. Best Pract Res Clin Anaesthesiol, 2003, 17(3): 407-428.
[19] Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review[J]. Am J Hosp Palliat Care, 2003, 20(1): 62-66.
[20] Anselmetti GC, Manca A, Montemurro F, et al. Percutaneous vertebroplasty in multiple myeloma: prospective longterm followup in 106 consecutive patients[J]. Cardiovasc Intervent Radiol, 2012, 35(1): 139-145. DOI: 10.1007/s0027001101114.
[21] Chew C, Ritchie M, O′Dwyer PJ, et al. A prospective study of percutaneous vertebroplasty in patients with myeloma and spinal metastases[J]. Clin Radiol, 2011, 66(12): 1193-1196. DOI: 10.1016/j.crad.2011.08.004.
[22]Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus nonsurgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial[J]. Lancet Oncol, 2011, 12(3): 225-235. DOI: 10.1016/S14702045(11)700080.
[23] Miller FG, Kallmes DF, Buchbinder R. Vertebroplasty and the placebo response[J]. Radiology, 2011, 259(3): 621-625. DOI: 10.1148/radiol.11102412.
[24] Hulme PA, Krebs J, Ferguson SJ, et al. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies[J]. Spine (Phila Pa 1976), 2006, 31(17): 1983-2001. DOI: 10.1097/01.brs.0000229254.89952.6b.
[25] Mudano AS, Bian J, Cope JU, et al. Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a populationbased cohort study[J]. Osteoporos Int, 2009, 20(5): 819-826. DOI: 10.1007/s0019800807455.
[26] Papanastassiou ID, Aghayev K, Berenson JR, et al. Is vertebral augmentation the right choice for cancer patients with painful vertebral compression fractures?[J]. J Natl Compr Canc Netw, 2012, 10(6): 715-719. |